• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Drug-Device Combinations

Medtronic Diabetes names CFO with consumer experience ahead of separation

July 8, 2025 By Sean Whooley

Chad Spooner Medtronic MiniMed CFO

Medtronic (NYSE:MDT) announced today that it appointed Chad Spooner as CFO of MiniMed in advance of its intended separation. Effective July 14, Spooner takes responsibility for overseeing the finance function for Medtronic Diabetes/MiniMed. His role includes supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as the unit prepares to become independent. The […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Personnel, Technology Tagged With: Medtronic, minimed, Personnel Moves

Diabeloop launches insulin delivery algorithm in Germany

July 8, 2025 By Sean Whooley

Diabeloop Sooil DBLG1 Dana-i pump Dexcom G6

Diabeloop today announced the commercial availability of its DBLG1 algorithm with the Dana-i insulin pump from Sooil in Germany. The companies distribute their automated insulin delivery offering through Mediq, a leading European diabetes provider. Mediq serves as the exclusive distributor for the DBLG1 system and the Dana-i pump by Sooil. Paris-based Diabeloop develops therapeutic artificial […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: Diabeloop, SOOIL

GlucoModicum has positive data for needle-free CGM

July 2, 2025 By Sean Whooley

GlucoModicum needle-free CGM (1)

GlucoModicum today announced positive outcomes from a clinical performance study of its needle-free continuous glucose monitor (CGM). Helsinki, Finland-based GlucoModicum said in a news release that the study helps put the company on “a clear path to commercialization.” The study involved 646 participant visits, including individuals with type 2 diabetes and healthy volunteers. The company […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: GlucoModicum

Lifecare takes next steps in CGM implant development

July 2, 2025 By Sean Whooley

Screenshot of the Lifecare implantable CGM technology

Lifecare said on social media that it completed a significant milestone in the development of its continuous glucose monitor (CGM) implant. The Norway-based company says it completed the initial electromagnetic compatibility (EMC) testing of electronics developed for its next-generation CGM implant. EMC testing ensures that the implant can operate reliably when surrounded by mobile phones, […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Implants, Patient Monitoring, Technology Tagged With: lifecare

Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

July 1, 2025 By Sean Whooley

Ypsomed YpsoMate 1mL autoinjector

Ypsomed announced today that Chinese regulatory authorities approved the a dual GCP/GLP-1 drug delivered using its auto-injector. The Chinese National Medical Products Administration (NMPA) approved Maxdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, developed by Innovent Biologics. It treats people with obesity through delivery with an YpsoMate 1.0 auto-injector variant. YpsoMate, a user-friendly […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Pharmaceuticals, Regulatory/Compliance Tagged With: Ypsomed

Convatec wins FDA approval for Parkinson’s treatment infusion tech

June 26, 2025 By Sean Whooley

ConvaTec

Convatec announced today that it received FDA approval for the delivery of a Parkinson’s disease therapy through its Neria Guard infusion set. The FDA approved apomorphine hydrochloride for subcutaneous infusion for the treatment of Parkinson’s. London-based Convatec’s Neria Guard set delivers the therapy under the skin (subcutaneous) as a continuous infusion via a small portable […]

Filed Under: Business/Financial News, Drug-Device Combinations, Food & Drug Administration (FDA), Neurological, Pharmaceuticals Tagged With: Convatec

The biggest diabetes tech stories out of ADA 2025

June 24, 2025 By Sean Whooley

ADA Logo in Chicago American Diabetes Association 85th Scientific Sessions

The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association’s 85th Scientific Sessions. At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, ADA 2025, Beta Bionics, biolinq, Dexcom, Eli Lilly & Co., Glucotrack, Insulet, LifePlus, mannkind, Medtronic, minimed, modularmedical, PharmaSens, Senseonics, Sequel Med Tech, SiBionics, Tandem Diabetes Care, Vaxess Technologies

Senseonics lays out hopes for next-gen CGM commercial timelines

June 24, 2025 By Sean Whooley

Senseonics Ascensia Eversense 365 product image separate components

Senseonics (NYSE:SENS) has offered some insight into its plans for its next-generation implantable continuous glucose monitors (CGMs). The maker of the Eversense 365 year-long implantable CGM hosted an analyst event during the American Diabetes Association’s 85th Scientific Sessions in Chicago this past weekend. At that event, the company touched on the commercial strategy for Eversense […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Implants, Patient Monitoring, Technology Tagged With: ADA 2025, Ascensia Diabetes Care, Senseonics

Mannkind looks to give those with diabetes another option through inhaled insulin

June 24, 2025 By Sean Whooley

MannKind afrezza inhaled insulin in use

For those living with diabetes, MannKind offers a very different alternative to the current methods of insulin delivery. Founded in 1991 by Alfred E. Mann, a medtech visionary who played a large part in the wider adoption of insulin pumps as the founder of MiniMed, the company develops Afrezza — a fast-acting insulin formulation delivered […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured Tagged With: ADA 2025, mannkind

Modular Medical study shows potential benefits of pump-delivered GLP-1s

June 24, 2025 By Sean Whooley

Modular Medical modd1 insulin pump

Modular Medical (Nasdaq:MODD) has shared new data highlighting the use of its insulin pump technology to deliver GLP-1 therapeutics. The company shared its findings in a poster presentation at the American Diabetes Association’s 85th Scientific Sessions in Chicago. San Diego-based Modular Medical develops the MODD1 product, a 90-day patch pump. It features new microfluidics technology […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Technology Tagged With: ADA 2025, modularmedical

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 335
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS